ECMM 2017 - Michael Hodges, M.D. - APX001: antifungal agent

preview_player
Показать описание
APX001 a broad-spectrum, novel mechanism of action, antifungal agent with potential to treat severe fungal infections

Michael Hodges, M.D., Chief Medical Officer, Amplyx Pharmaceutical, USA

16:15 - 16:30 Uhr 10.10.2017

Stream powered by NCXT.de
Рекомендации по теме
Комментарии
Автор

The buildup of azoles (the doctors suspect) in my wife's body has caused severe peripheral neuropathy to the point she can't walk or hold anything without aide. She will be starting a treatment of Fosmanogepix in hopes of reversing the neuropathy. She has tried all existing anti-fungal meds and a regiment of amphotericin infusions, so this experimental drug is the last option to combat her coccidioidomycosis meningitis. If you have any information regarding this drug or any other thoughts, I would appreciate it.

Blaze_
Автор

Oh my God, i cannot tolerate the person sitting RIGHT NEXT TO THE MIC coughing, and coughing, and coughing!

KaldonisPondo
welcome to shbcf.ru